TNF and inflammatory bowel disease: Biologic therapies (e.g., anti-TNF agents such as infliximab/adalimumab, anti-integrin vedolizumab) and anti-interleukin agents (Ustekinumab) [122] target specific inflammatory pathways in the intestinal tract and have transformed IBD management [122].